The approval of prolonged-acting cabotegravir injected once each two months expands biomedical HIV avoidance selections accessible to persons in the United States, providing a substitute for day-to-day oral tablets. one MB) to boost awareness, detect priorities, and challenge distinct tips to address the effects of your epidemic in Hispanic/Latino communities. https://www.directivepublications.org/journal-of-hiv-aids-research/